Sunitinib Malate
Spécifications
341031-54-7Numéro CAS
638-825-9Numéro CE
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acidNom IUPAC
C26H33FN4O7Formule chimique
532.6 g/molMasse molaire
Sunitinib malate; 341031-54-7; SU011248 L-malate salt; PHA-290940AD; sunitinib L-malate; SU010398; SU-011248 L-malate salt; DTXSID4046492; LVX8N1UT73; SU-010398; DTXCID801476195; NSC736511; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); RefChem:56081; Sutent; Sunitinib malate [USAN]; MFCD08282795; Sunitinib (Malate); N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; SU 11248; CAS-341031-54-7; NCGC00164631-01; UNII-LVX8N1UT73; SU 011248; Sutent;; C26H33FN4O7; PDGF TK antagonist; Sutent (TN); Sutent (TN) (Pfizer); Sunitinib Malate (Sutent); CHEMBL1567; SU-11248 L-malate salt; SUNITINIB MALATE [MI]; Sunitinib malate (JAN/USAN); SUNITINIB MALATE [JAN]; orb1225255; orb1310676; SCHEMBL1258610; Sunitinib (Malate) (Standard); SCHEMBL29371243; SUNITINIB MALATE [VANDF]; SUNITINIB MALATE [MART.]; CHEBI:232546; PNU-290940AD; SUNITINIB MALATE [WHO-DD]; HMS3261H09; HMS6018J17; Sunitinib malate, >=98% (HPLC); Tox21_112249; Tox21_500514; HY-10255R; SU-11248J; Sunitinib malate - Bio-X trade mark; AKOS005145765; AKOS025149097; Sunitinib Malate (Sunitinib L-Malate); SUNITINIB MALATE [ORANGE BOOK]; Tox21_112249_1; CCG-221818; CS-0177; EBC-218028; FS10822; KS-5023; NCGC00164631-05; NCGC00261199-01; BP-43644; BS164428; HY-10255; MS-33338; SY075040; SU-11248;; SW219407-1; D06402; Q27283213; (2S)-2-Hydroxybutanedioic acid--N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1/1); (2S)-2-hydroxybutanedioic acid; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(S)-2-hydroxysuccinate; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, malate salt; N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimehyl-1H-pyrrole-3-carboxamide malate; N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Malate; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acidSynonymes
Produits contenant Sunitinib Malate
수텐캡슐50밀리그램(수니티닙말산염)수텐캡슐25밀리그램(수니티닙말산염)수텐캡슐12.5밀리그램(수니티닙말산염)SUNITINIB TILLOMED 50 MG CAPSULAS DURAS EFGSUNITINIB TILLOMED 25 MG CAPSULAS DURAS EFGSUNITINIB TILLOMED 12,5 MG CAPSULAS DURAS EFGSUNITINIB SILVER 50 MG CÁPSULAS DURAS EFGSUNITINIB SILVER 25 MG CÁPSULAS DURAS EFGSUNITINIB SILVER 12,5 MG CÁPSULAS DURAS EFGSUNITINIB KOANAA 50 MG CAPSULAS DURAS EFGSUNITINIB KOANAA 37,5 MG CAPSULAS DURAS EFGSUNITINIB KOANAA 25 MG CAPSULAS DURAS EFG
Page 1 sur 4
Entreprises vendant Sunitinib Malate
HD
Hangzhou Dingyan Chem Co., LtdChinaZE
Zhejiang Eazy Pharmchem Co., Ltd.ChinaSD
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTDChinaWH
Wuxi Hexia Chemical CompanyChinaTE
Tecnimede España Industria Farmaceutica S.A.SpainPE
PFIZER EUROPE MA EEIGBelgium한국
한국화이자제약(주)Republic of KoreaRP
Reddy Pharma Iberia S.A.SpainPage 1 sur 2